These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24932669)

  • 1. Forcefield_NCAA: ab initio charge parameters to aid in the discovery and design of therapeutic proteins and peptides with unnatural amino acids and their application to complement inhibitors of the compstatin family.
    Khoury GA; Smadbeck J; Tamamis P; Vandris AC; Kieslich CA; Floudas CA
    ACS Synth Biol; 2014 Dec; 3(12):855-69. PubMed ID: 24932669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forcefield_PTM:
    Khoury GA; Thompson JP; Smadbeck J; Kieslich CA; Floudas CA
    J Chem Theory Comput; 2013 Dec; 9(12):5653-5674. PubMed ID: 24489522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of structure-activity relations of complement inhibitor compstatin.
    Soulika AM; Morikis D; Sarrias MR; Roy M; Spruce LA; Sahu A; Lambris JD
    J Immunol; 2003 Aug; 171(4):1881-90. PubMed ID: 12902490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids.
    Mallik B; Katragadda M; Spruce LA; Carafides C; Tsokos CG; Morikis D; Lambris JD
    J Med Chem; 2005 Jan; 48(1):274-86. PubMed ID: 15634022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.
    Tamamis P; Pierou P; Mytidou C; Floudas CA; Morikis D; Archontis G
    Proteins; 2011 Nov; 79(11):3166-79. PubMed ID: 21989937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational analysis of complement inhibitor compstatin using molecular dynamics.
    Devaurs D; Antunes DA; Kavraki LE
    J Mol Model; 2020 Aug; 26(9):231. PubMed ID: 32789582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.
    Qu H; Magotti P; Ricklin D; Wu EL; Kourtzelis I; Wu YQ; Kaznessis YN; Lambris JD
    Mol Immunol; 2011 Jan; 48(4):481-9. PubMed ID: 21067811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations.
    Tamamis P; Morikis D; Floudas CA; Archontis G
    Proteins; 2010 Sep; 78(12):2655-67. PubMed ID: 20589629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
    Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD
    Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Testing of Force Field Parameters for Phenylalanine and Tyrosine Derivatives.
    Wang X; Li W
    Front Mol Biosci; 2020; 7():608931. PubMed ID: 33385013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEPstrMOD: structure prediction of peptides containing natural, non-natural and modified residues.
    Singh S; Singh H; Tuknait A; Chaudhary K; Singh B; Kumaran S; Raghava GP
    Biol Direct; 2015 Dec; 10():73. PubMed ID: 26690490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
    Sahu A; Soulika AM; Morikis D; Spruce L; Moore WT; Lambris JD
    J Immunol; 2000 Sep; 165(5):2491-9. PubMed ID: 10946275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of noncanonical amino acids into Rosetta and use in computational protein-peptide interface design.
    Renfrew PD; Choi EJ; Bonneau R; Kuhlman B
    PLoS One; 2012; 7(3):e32637. PubMed ID: 22431978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New compstatin peptides containing N-terminal extensions and non-natural amino acids exhibit potent complement inhibition and improved solubility characteristics.
    Gorham RD; Forest DL; Khoury GA; Smadbeck J; Beecher CN; Healy ED; Tamamis P; Archontis G; Larive CK; Floudas CA; Radeke MJ; Johnson LV; Morikis D
    J Med Chem; 2015 Jan; 58(2):814-26. PubMed ID: 25494040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles.
    Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD
    Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition.
    Janssen BJ; Halff EF; Lambris JD; Gros P
    J Biol Chem; 2007 Oct; 282(40):29241-7. PubMed ID: 17684013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory studies of ab initio protein structure prediction: multiple copy simulated annealing, AMBER energy functions, and a generalized born/solvent accessibility solvation model.
    Liu Y; Beveridge DL
    Proteins; 2002 Jan; 46(1):128-46. PubMed ID: 11746709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of compstatin in Escherichia coli: incorporation of unnatural amino acids enhances its activity.
    Katragadda M; Lambris JD
    Protein Expr Purif; 2006 May; 47(1):289-95. PubMed ID: 16406678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin.
    Katragadda M; Morikis D; Lambris JD
    J Biol Chem; 2004 Dec; 279(53):54987-95. PubMed ID: 15489226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermodynamics calculation of protein-ligand interactions by QM/MM polarizable charge parameters.
    Wang J; Shao Q; Cossins BP; Shi J; Chen K; Zhu W
    J Biomol Struct Dyn; 2016; 34(1):163-76. PubMed ID: 25761118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.